论文部分内容阅读
Lung cancer is the leading cause of cancer-related deaths worldwide.Jinfukang (JFK), an oral liquid prescription of Chinese herbal drugs, has been clinically available for the treatment of non-small cell lung cancer (NSCLC).Lymphangiogenesis is a primary event in the process of cancer development and metastasis, and the formation and migration of lymphatic endothelial cells (LECs) play a key role in the lymphangiogenesis.To assess the activity of stromal cell-derived factor-1 (SDF-1) and coeffect of SDF-1 and vascular endothelial growth factor-C (VEGF-C) on the formation and migration of LECs, and to clarify the inhibitory effects of JFK on the LECs, the LECs were differentiated from CD34+/VEGFR-3+ endothelial progenitor cells (EPCs), and JFK-containing serums were prepared from rats.SDF-1 and VEGF-C both induced the differentiation of CD34+/VEGFR-3+ EPCs towards LECs, and enhanced LECs migration.Co-use of SDF-1 and VEGF-C displayed an additive effect on the differentiation, but did not on LECs migration.JFK inhibited the differentiation and migration of LECs, and the inhibitory effects were most probably via regulation of the SDF-1/CXCR4 and VEGF-C/VEGFR3 axises.The current findings suggested that JFK might inhibit NSCLC through anti-lymphangiogenesis, and also provided a potential to discover anti-lymphangiogenesis agents from natural resources.